More expanded access for DMP 266

An expanded access program for DMP 266 (Sustiva/efavirenz) is now available to people with less than 400 T-cells and on failing therapy. Studies show DMP 266 is effective with Combivir (AZT/3TC), a combination that does not include a protease inhibitor. DuPont Merck warns that it may not be effective in people who have taken other non-nucleoside analogues that have similar resistance patterns.